<code id='4D8BC96561'></code><style id='4D8BC96561'></style>
    • <acronym id='4D8BC96561'></acronym>
      <center id='4D8BC96561'><center id='4D8BC96561'><tfoot id='4D8BC96561'></tfoot></center><abbr id='4D8BC96561'><dir id='4D8BC96561'><tfoot id='4D8BC96561'></tfoot><noframes id='4D8BC96561'>

    • <optgroup id='4D8BC96561'><strike id='4D8BC96561'><sup id='4D8BC96561'></sup></strike><code id='4D8BC96561'></code></optgroup>
        1. <b id='4D8BC96561'><label id='4D8BC96561'><select id='4D8BC96561'><dt id='4D8BC96561'><span id='4D8BC96561'></span></dt></select></label></b><u id='4D8BC96561'></u>
          <i id='4D8BC96561'><strike id='4D8BC96561'><tt id='4D8BC96561'><pre id='4D8BC96561'></pre></tt></strike></i>

          fashion

          fashion

          author:focus    Page View:1975
          A scientist working at SQZ Biotechnologies in Watertown's Arsenal Yards. -- biotech coverage from STAT
          A scientist working at SQZ Biotechnologies in Watertown, Mass. David L Ryan/Globe Staff

          Next stop: Beacon Hill.

          Governor Maura Healey’s long-awaited plan to double down on state funding for the biotech and medical technology sector came into focus Thursday with the announcement she’ll seek $1 billion over the next decade to reauthorize the state’s 16-year-old life sciences initiative.

          advertisement

          But lawmakers so far are noncommittal on funding the plan. The proposal — dubbed “Life Sciences 3.0″ — is part of a larger economic development bill the Healey administration is expected to file soon. Several expressed support for an industry in which Massachusetts is a leader, but also noted the spending request comes at a time of competing priorities.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          Report cites 'urgent' need to recruit more diverse clinical trial participants
          Report cites 'urgent' need to recruit more diverse clinical trial participants

          AdobeThepersistentlackofdiversityamongparticipantsinclinicaltrialsisacriticalissuethatisharmingbothp

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          Senate panel eyes new effort on drug shortages

          Sen.RonWyden,D-Ore.,left,andSen.MikeCrapo,R-Idaho,right,walkonCapitolHillin2021.SusanWalsh/APWASHING